Grey Wolf Therapeutics
Latest round
- Series B
Last raised
- May 2024
Total raised
- $130M
Investors
- 7
About Grey Wolf Therapeutics
Founded in 2017 in the UK, Grey Wolf Therapeutics Limited focuses on developing advanced immunotherapies.Grey Wolf Therapeutics focuses on innovative antigen modulation technology aimed at enhancing immune system functionality. Their flagship product, GRWD5769, is currently undergoing a Phase 1/2 clinical trial in oncology, demonstrating significant proof-of-mechanism and target engagement. This technology effectively modifies antigen presentation, enabling T cells to better recognize and target malignant or dysfunctional cells. The company's active discovery and development programs span multiple therapeutic areas, including oncology, autoimmunity, and virology, addressing significant unmet medical needs.Grey Wolf Therapeutics generates revenue through partnerships and collaborations with biopharmaceutical companies and research institutions, focusing on advancing their antigen modulation technology. The revenue model includes transaction structures based on milestone payments and royalties tied to the development and eventual commercialization of their lead product, GRWD5769, along with other pipeline candidates. The company engages in business-to-business (B2B) relationships, providing access to their proprietary technology and therapeutic solutions to partners involved in drug development. The company aims to accelerate the development of new products targeting significant unmet medical needs in these therapeutic areas. Additionally, Grey Wolf Therapeutics is exploring opportunities to enter new markets in North America and Europe, aiming to broaden their reach in the biopharmaceutical sector by 2025.
Who invested in Grey Wolf Therapeutics
7 investors across 6 rounds
See all investors in Grey Wolf Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Grey Wolf Therapeutics
Who invested in Grey Wolf Therapeutics?
Grey Wolf Therapeutics has 7 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Grey Wolf Therapeutics raised?
Grey Wolf Therapeutics has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Grey Wolf Therapeutics last raise money?
Grey Wolf Therapeutics's most recent round on record is a Series B, in May 2024.
What does Grey Wolf Therapeutics do?
Founded in 2017 in the UK, Grey Wolf Therapeutics Limited focuses on developing advanced immunotherapies.
Where is Grey Wolf Therapeutics headquartered?
Grey Wolf Therapeutics is headquartered in UK.
Which VCs invest in companies like Grey Wolf Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Grey Wolf Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Grey Wolf Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.